Active ingredientVorinostatCat. No. P-V062-001CAS 149647-78-9Family · Pharmaceutical analytical standards
Vorinostat
The first histone deacetylase (HDAC) inhibitor approved by the FDA, in 2006, for the skin manifestations of cutaneous T-cell lymphoma that persists or returns after other therapies. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?It stems from a finding Charlotte Friend published in 1971: the solvent DMSO made mouse leukaemia cells mature into red blood cells; Paul Marks and Ronald Breslow sought more potent analogues and arrived at SAHA.
Go to the active ingredient →Active ingredientVorinostatCat. No. P-V062-001CAS 149647-78-9
Isotopically labelledVorinostat-d5Cat. No. P-V062-003CAS 1132749-48-4
ImpurityN-PhenyloctanediamideCat. No. P-V062-004CAS 1305124-48-4
ImpurityVorinostat Impurity 1Cat. No. P-V062-005CAS 866824-87-5
Impurityp-Aminomethyl VorinostatCat. No. P-V062-006CAS 1160823-16-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.